key: cord-0728411-ipzaubya authors: Angurana, Suresh Kumar; Awasthi, Puspraj; Thakur, Ajay; Randhawa, Manjinder Singh; Nallasamy, Karthi; Kumar, Manoj Rohit; Naganur, Sanjeev; Kumar, Mahendra; Goyal, Kapil; Ghosh, Arnab; Bansal, Arun; Jayashree, Muralidharan title: Intensive care needs and short-term outcome of Multisystem Inflammatory Syndrome in Children (MIS-C): Experience from North India date: 2021-06-25 journal: J Trop Pediatr DOI: 10.1093/tropej/fmab055 sha: 8c3c93c84896ad7f1052a0b9aa9aa6fc88d81417 doc_id: 728411 cord_uid: ipzaubya OBJECTIVES: To describe the intensive care needs and outcome of Multisystem Inflammatory Syndrome in Children (MIS-C). METHODOLOGY: This retrospective study was conducted in the Pediatric Emergency and Intensive Care Units and COVID-19 hospital of a tertiary care teaching and referral hospital in North India over a period of 5 months (September 2020-January 2021). Clinical details, laboratory investigations, intensive care needs, treatment, and short-term outcome were recorded. RESULTS: Forty children with median (IQR) age of 7 (5-10) years were enrolled. The common clinical features were fever (97.5%), mucocutaneous involvement (80%), abdominal (72.5%) and respiratory (50%) symptoms. Shock was noted in 80% children. Most cases (85%) required PICU admission where they received nasal prong oxygen (40%), non-invasive (22.5%) and invasive (22.5%) ventilation, and vasoactive drug support (72.5%). The confirmation of SARS-CoV-2 exposure was noted in the form of positive serology (66.7%), RT PCR (10%), and contact with SARS-CoV-2 positive case (12.5%). The common echocardiographic findings included myocardial dysfunction (ejection fraction <55%) (72.5%), and coronary artery dilatation or aneurysm (22.5%). The immunomodulatory treatment included IVIG (2 gm/kg) (100%) and steroids (methylprednisolone 10-30 mg/kg/day for 3-5 days) (85%). Aspirin was used in 80% and heparin (low molecular weight) in 7.5% cases. Two children died (5%) and median duration of PICU and hospital stay in survivors were 5 (2-8) and 7 (4-9) days, respectively. Children with shock showed higher total leucocyte count and higher rates of myocardial dysfunction. CONCLUSION: Cardiovascular involvement and shock are predominant features in severe disease. Early diagnosis may be challenging given the overlapping features with other diagnoses. A high index of suspicion is warranted in children with constellation of fever, mucocutaneous, GI and cardiovascular involvement alongwith evidence of systemic inflammation and recent or concurrent SARS-CoV-2 infection. The short-term outcome is good with appropriate organ support therapies and immunomodulation. Objectives: To describe the intensive care needs and outcome of Multisystem Inflammatory Syndrome in Children (MIS-C). Methodology: This retrospective study was conducted in the Pediatric Emergency and Intensive Care Units and COVID-19 hospital of a tertiary care teaching and referral hospital in North India over a period of 5 months (September 2020-January 2021). Clinical details, laboratory investigations, intensive care needs, treatment, and short-term outcome were recorded. Results: Forty children with median (IQR) age of 7 (5-10) years were enrolled. The common clinical features were fever (97.5%), mucocutaneous involvement (80%), abdominal (72.5%) and respiratory (50%) symptoms. Shock was noted in 80% children. Most cases (85%) required PICU admission where they received nasal prong oxygen (40%), non-invasive (22.5%) and invasive (22.5%) ventilation, and vasoactive drug support (72.5%). The confirmation of SARS-CoV-2 exposure was noted in the form of positive serology (66.7%), RT PCR (10%), and contact with SARS-CoV-2 positive case (12.5%). The common echocardiographic findings included myocardial dysfunction (ejection fraction <55%) (72.5%), and coronary artery dilatation or aneurysm (22.5%). The immunomodulatory treatment included IVIG (2 gm/kg) (100%) and steroids (methylprednisolone 10-30 mg/kg/day for 3-5 days) (85%). Aspirin was used in 80% and heparin (low molecular weight) in 7.5% cases. Two children died (5%) and median duration of PICU and hospital stay in survivors were 5 (2-8) and 7 (4-9) days, respectively. Children with shock showed higher total leucocyte count and higher rates of myocardial dysfunction. Conclusion: Cardiovascular involvement and shock are predominant features in severe disease. Early diagnosis may be challenging given the overlapping features with other diagnoses. A high index of suspicion is warranted in children with constellation of fever, mucocutaneous, GI and cardiovascular involvement alongwith evidence of systemic inflammation and recent or concurrent SARS-CoV-2 infection. Healthcare systems globally have been severely burdened by the coronavirus disease 2019 (COVID-19) pandemic. 1- 6 The disease has been severe in adults typically occurring in the 2 nd week of illness coinciding with increase in inflammatory markers and decrease in viral load. The aberrant and dysregulated innate and adaptive immune response is thought to be the cause of host tissue damage. [7] [8] [9] [10] [11] On the other hand, children were less frequently and less severely affected, especially in the early part of the pandemic. 1-3, 12 Severe and critical disease was reported in only 5.8% in a study from China. 12 The first report of severe disease in children temporally associated with COVID-19 came from the United Kingdom (UK) in late April 2020 in a cluster of eight previously healthy children who presented with fever, shock, and hyperinflammation. This constellation was labelled as pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). 13 Thereafter, multiple reports of PIMS-TS, multisystem inflammatory syndrome in children (MIS-C), Kawasaki disease (KD), Kawasaki-like syndrome, or toxic shock syndrome (TSS) were increasingly reported from other countries as well. However, only <100 cases of PIMS-TS or MIS-C have been reported from India till date. [37] [38] [39] [40] In order to reduce the morbidity and mortality associated with MIS-C, it is important to study the disease spectrum, clinical features, evolution, treatment and outcome. The sicker cohort in particular needs to be studied for its PICU needs, complications, and outcome. More importantly since the clinical features of MISC closely mimics other common PICU admissions like TSS and tropical infections. it is important to raise awareness about this condition to facilitate early diagnosis and prompt treatment. In view of limited data from India, we planned this study to describe the clinical characteristics, intensive care needs, and shortterm outcome of children with MIS-C. This retrospective study was conducted in the Pediatric Emergency, Pediatric Intensive Care Unit (PICU), and COVID-19 hospital of a tertiary care teaching and referral hospital in North India from 1 st September 2020 to 31 st January 2021. Data of 40 children between 3 months to 12 years with diagnosis of MIS-C was retrieved from the admission files and patient electronic database and recorded on a pre-designed study proforma. The study protocol was approved by the Institute Ethics Committee and the final manuscript was approved by the Departmental Review Board. The details included age, gender, underlying co-morbidity (obesity, congenital cardiac disease, chronic lung disease, neurological disease, neuromuscular disorder, or any other), presenting complaints, duration of illness, and pre-referral treatment. The evidence of recent or concurrent SARS-CoV-2 infection (SARS-CoV-2 antibody, RT-PCR, and contact/epidemiological link in 2-6 weeks prior) were also noted. The laboratory details included complete blood count, renal function tests, liver function tests, coagulation profile, C- steroids, and immunomodulators were recorded. The final outcomes including mortality, length of PICU and hospital stay were recorded. The diagnosis of MIS-C was made on the basis of case definition given by the WHO (https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndromein-children-and-adolescents-with-covid-19). The diagnosis of recent or current COVID-19 was The definitions for various laboratory parameters included: hyponatremia as serum sodium <135 meq/L, lymphopenia as absolute lymphocyte count <3000/cumm for infants and <1000/cumm for older children, thrombocytopenia as platelet count <1,50,000/cumm, elevated CRP >10 mg/dl, elevated procalcitonin >0.2 ng/ml, elevated ferritin >500 ng/ml, elevated Ddimer >500 ng/ml, elevated fibrinogen >4 gm/L, and elevated NT-proBNP as >125 pg/ml. The myocardial dysfunction was defined as left ventricular ejection fraction (LVEF) <55%. The coronary artery dilatation or aneurysm was defined as coronary artery diameter ≥2.5 z score and giant aneurysm as ≥10 z score or >8 mm. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Results: Forty children with MIS-C were admitted during the study period. The month wise distribution is given in Figure 1 ; the highest number of cases were admitted in the month of October 2020 (n=11). The median (IQR) age of the enrolled subjects was 7 (5-10) years and 65% (n=26) were boys. The median (IQR) duration of symptoms before hospitalisation was 6 (5-7) days and most common clinical features were fever (97.5%); mucocutaneous (80%) including rash (72.5%), conjunctival injection (60%), oral mucosal changes (27.5%), and extremity changes (17.5%); abdominal (72.5%) including abdominal pain (57.5%), vomiting (50), and diarrhea (30%); and respiratory (50%) including rapid breathing (40%) and cough (25%). Four (10%) cases had hemorrhagic non-purulent conjunctivitis (Figure 2a (Table 1) . Table 2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 in one case 2 weeks after discharge) which recovered spontaneously. Two children (5%) developed peripheral gangrene of bilateral toes during admission which resolved at the time of discharge (Figure 2c and 2d ). All cases underwent echocardiography. The common echocardiographic findings were LVEF <55% (72.5%), coronary artery dilatation or aneurysm (22.5%), and giant coronary aneurysm (2.5%). None had pericardial effusion. At discharge, residual myocardial dysfunction was noted in 15% (n=6) cases. Majority (85%) of the cases required PICU admission. The highest level of respiratory support received were nasal prong oxygen (40%), non-invasive ventilation (22.5%), invasive ventilation (22.5%), and HFNC (2.5%). Shock was present in 80% cases out of which 81.2% required fluid bolus/es and 90.6% (72.5% of total cohort, 29/40) required vasoactive drug support for a median duration of 81 (48-120) hours with highest median VIS score being 20 . Not all children with shock received fluid boluses in view of suspected myocardial dysfunction. Acute kidney injury was seen in 45% cases but none required RRT. All cases received IVIG soon after admission in dose of 2 gm/kg over 12-24 hours. Only one child (2.5%) required an additional dose of IVIG for non-improvement after first dose IVIG and steroids. Steroids were used in 85% cases, the most common steroid being methylprednisolone (82.5%) in dose of 10 mg/kg/day (75.3%) for 3-5 days followed by oral prednisolone for 4-6 weeks. The methylprednisolone was usually started at dose of 10 mg/kg/day and if there was no improvement in next 24-48, the dose was increased to 20 or 30 mg/kg/day. Steroid and IVIG (combined) was used in 85% cases. Aspirin was started in 80% cases in a dose of 3 mg/kg/day (maximum daily dose 75 mg) for a minimum of 4 weeks. The anticoagulation (low molecular weight heparin) was used in 7.5% cases (including 2 cases with peripheral gangrene). The median length of PICU and hospital stay were 5 (2-8) days and 7 (4-9) days, respectively. Two (5%) children died due to refractory shock within 24 hours of admission (Table 4 ). 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Children with shock had significantly higher rates of myocardial dysfunction (p=0.02), higher total leukocyte count (p=0.048), and higher proportion of them received steroids (p=0.009). Although children with shock were relatively younger; had lower ejection fraction, platelet count, and fibrinogen levels; higher ferritin, D-dimer, pro-BNP, CRP, and procalcitonin levels; higher proportion needed PICU care; and had longer PICU and hospital stay, the difference in these parameters was not statistically significant (Table 5 ). 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 We describe the largest cohort of critically ill children with MIS-C from North India with respect to their clinical and laboratory characteristics, intensive care needs, and outcome. As opposed to COVID 19 which was less in frequency and severity in children, MIS-C tends to be more severe. It is postulated to be a post-SARS-CoV-2 phenomenon, characterised by multiple organ dysfunction (gastrointestinal, mucocutaneous, and cardiovascular) and a critical course secondary to immune-mediated injury, hyperinflammation, and hypercytokinemia. 11, 14, 16 Unlike in children with acute COVID-19, the involvement of respiratory system is less frequent. A post viral hypothesis is supported by lower rates of SARS-CoV-2 RT-PCR positivity and higher rates of SARS-CoV-2 positive serology, [14] [15] [16] [17] 36 a finding that was observed in our cohort too. Furthermore, the peak incidence of MIS-C is reported to occur about 2-6 weeks after the COVID-19 peak. 14-17, 31, 43 Early diagnosis of MIS-C can be challenging given the overlapping features with other diseases. Symptoms mimicking GI infection, acute abdomen, or inflammatory bowel disease attributed to vasculitis induced bowel wall edema or ischemia, cardiac dysfunction and/or shock, mesenteric lymphadenitis, and mesenteric inflammation have been reported. 14, 16-27, 29, 31, 35, 36. 44 Similarly, the neurological manifestations (seizure, encephalopathy, meningismus, headache) although uncommon in our cohort (2.5%) have also been reported previously in children with MIS-C (10-55%). [35] [36] [37] 40 Kawasaki Disease, TSS, macrophage activation syndrome (MAS), or hemophagocytic lymphohistiocytosis (HLH) are the other close differential diagnoses. 16, 17 Older age group (7-10 years), more GI, respiratory and 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 cardiovascular system (shock, LV dysfunction) involvement, marked hyper-inflammation (elevated CRP, procalcitonin, ferritin, lymphopenia, and thrombocytopenia), and higher need for organ support therapies (vasoactive drugs and mechanical ventilation) differentiates MIS-C from KD. 11, 13, 14, 16, 17, 21, 31 Diagnosis of MIS-C warrants a high index of suspicion. Any child with history of SARS-CoV-2 infection (asymptomatic or symptomatic), 2-6 weeks prior to the symptom onset, presenting with constellation of fever, mucocutaneous features, GI symptoms, and shock should alert pediatricians towards this entity. Broadly, the diagnosis of MIS-C requires presence of fever, severe illness requiring hospitalization with ≥1 organ dysfunction, elevated markers of inflammation, evidence of current or recent SARS-CoV2-2 infection (positive SARS-CoV-2 RT PCR or serology or epidemiological contact), and exclusion of other alternative etiologies. 14, 16, 17, 35, 45 Majority of the affected children in our cohort had shock, and required PICU admission, close monitoring and organ support therapies (vasoactive support and mechanical ventilation). It has been reported in literature that 65-88% of children with MIS-C require PICU admission 14-17, 36, 46 as was the case in most of our children. Shock in children with MIS-C is multifactorial contributed by myocardial dysfunction, vasoplegia, and vasculitis. 25 Although we did not identify any clinical or laboratory variable that could significantly predict the development of shock, we found that a significant proportion of children with shock had higher leucocyte count and myocardial dysfunction. The patterns of myocardial involvement described in MIS-C include LEVF <55% (50-70% children), myocarditis (50-80%), coronary artery dilatation or aneurysm (6-20%), and residual myocardial dysfunction at discharge (2-18%). 14, 15, 35, 36, 47, 48 The type of myocardial involvement seen in our cohort was similar. The biomarkers of hyperinflammation and organ dysfunction should be monitored closely in critically ill children as they help both in diagnosis and in monitoring the therapeutic 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 response. Majority of children in the index study had elevated markers of inflammation (CRP, procalcitonin, fibrinogen, ferritin, D-dimer), lymphopenia, and thrombocytopenia, similar to previously published reports 14, 15, 35, 36, 47 and showed an improvement following treatment. The major goals of treatment of MIS-C include control of systemic inflammation, organ support, and decrease the risk of long-term sequelae. 49 The intensive care needs reported in literature are: non-invasive (13-31%) or invasive (19-37%) ventilation, vasoactive drugs (53-73%), and renal replacement therapy (1-4%). The targeted therapies used in children were IVIG (74-89%), and steroids (40-65%). The antiplatelet agent (aspirin) and anticoagulation were used in 30-78% and 25-77% children, respectively. Although there has been a great variation in the use of immunomodulatory treatments for MIS-C, we had put in place an evidenced based protocol which we followed uniformly for all children. 41, 42, 50 We used IVIG in all cases with MIS-C and added steroids in those with moderate to severe illness and/or shock. There is some evidence to suggest that combination of IVIG and methylprednisolone as against IVIG alone was associated with rapid resolution of fever; lower treatment failure, lesser need for secondline therapy, and hemodynamic support; faster recovery of myocardial function; and shorter duration of PICU stay. 51, 52 Despite the multisystemic involvement and shock, the mortality in our cohort was low highlighting the importance of timely diagnosis, organ support and immunomodulatory therapies. The two deaths that occurred in our cohort, was due to refractory shock and occurred within 24 hours of admission further underscoring the importance of early recognition, resuscitation (fluids and vasoactive drugs), and targeted immunomodulation preferably at first contact healthcare facility. The strengths of this study are that it reports the largest critically ill cohort of MIS-C from India focussing on their intensive care needs and outcome. All the children were managed using uniform guidelines and protocols. The study however suffers from the inherent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 limitations of a single centre retrospective analysis. The SARS-CoV-2 serology could not be performed in all the children. A long-term follow-up to evaluate for persistent myocardial dysfunction and coronary artery abnormalities would have made the data more robust. MIS-C is a severe multisystemic manifestation of SARS-CoV-2 infection in children. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 18. Whittaker 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review SARS-CoV-2 Infection in Children Clinical Features and Outcome of SARS-CoV-2 Infection in Children: A Systematic Review and Meta-analysis. Indian Pediatr The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: A meta-analysis and systematic review Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and metaanalysis Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study Clinical Characteristics of Coronavirus Disease 2019 in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19: immunopathology and its implications for therapy Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children Epidemiology of COVID-19 Among Children in China Hyperinflammatory shock in children during COVID-19 pandemic Multisystem Inflammatory Syndrome in U.S. Children and Adolescents SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study Acute myocardial injury: a novel clinical pattern in children with COVID-19 Clinico-laboratory profile, intensive care needs, treatment details, and outcome of Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): A systematic review and Metaanalysis Clinicolaboratory Profile, Treatment, Intensive Care Needs, and Outcome of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2: A Systematic Review and Meta-analysis Epidemiological and Clinical Profile of Pediatric Inflammatory Multisystem Syndrome -Temporally Associated with SARS-CoV-2 (PIMS-TS) in Indian Children Multisystem Inflammatory Syndrome in Children With COVID-19 in Mumbai Multisystem Inflammatory Syndrome in Children: Clinical Features and Management-Intensive Care Experience from a Pediatric Public Hospital in Western India Unusual Clinical Manifestations and Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 2. Arthritis Rheumatol Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019 in a Children's Hospital in New York City: Patient Characteristics and an Institutional Protocol for Evaluation, Management, and Follow-Up. Pediatr Crit Care Med Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children Critical appraisal of qualitative research: necessity, partialities and the issue of bias Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection Multisystem Inflammatory Syndrome in Children in New York State COVID-19-Associated Multisystem Inflammatory Syndrome in Children -United States System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Table 4: Intensive care needs, treatment details, and outcome in children with MIS-C. Characteristics Total cases Shock, n (%) Fluid bolus, n (%) Vasoactive drugs, n (%) Adrenaline, n (%) Milrinone, n (%) Noradrenaline, n (%) Vasopressin, n (%) median (IQR) Duration of vasoactives in hours, median (IQR) , n (%) AKI stages (KDIGO) I, n (%) Steroids used: Methylprednisolone, n (%) Dexamethasone, n (%) Methylprednisolone dose: 10 mg/kg/day, n (%) 20 mg/kg/day, n (%) 30 mg/kg/day, n (%) in days Coronary artery dilatation or aneurysm, n (%) 9 (22.5) Coronary giant aneurysm, n (%) 1 (2.5) Residual myocardial dysfunction at discharge, n (%) 6 (15) Table 3 : Laboratory parameters at admission in children with MIS-C. Total cases, n=40 Hemoglobin (gm%) 10 (9-11.7) Total leukocyte count (per mm 3 ) 10250 (5000-16250) Absolute neutrophil count (per mm 3 ) 8256 (3713-13248) Absolute lymphocyte count (per mm 3 ) 1467 (800-2760) Platelet count (per mm 3